Provincial experiments aim to lower public drug plan costs
- Pharmaceutical policies in Canada: another example of federal-provincial discord. Anis, Aslam H. // CMAJ: Canadian Medical Association Journal;2/22/2000, Vol. 162 Issue 4, p523
AbstractPharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market...
- CAPITAL CAPSULES. Conlan, Michael F. // Drug Topics;3/5/2001, Vol. 145 Issue 5, p30
Presents political update on the pharmaceutical industry in the United States as of March 5, 2001. Claim of the Congress regarding the effect of volume discounts for drug purchases on Medicare costs; Legislators who proposed prescription restrictions to RU-486; Tests being conducted in...
- 'Patchwork' of state rules hampers wholesalers. // Chain Drug Review;6/11/2012, Vol. 34 Issue 10, p28
The article reports on the imposition of inconsistent and new pedigree requirements affecting distributors, pharmacies, manufacturers, and other authorized pharmaceutical dispensers under the state rules of more than half of the U.S. states.
- New Zealand and Australia: joint medicines regulatory body. // WHO Drug Information;2001, Vol. 15 Issue 2, p76
Reports on the New Zealand Health Minister's plan to explore the possibility of a joint trans-Tasman medicines, medical devices and dietary supplements regulatory body. Responsibilities of the proposed agency; Benefits of having a single set of regulations between New Zealand and Australia.
- Can pharmaceutical companies contribute to the quality use of medicines? Mansfield, Peter R. // Australian Prescriber;Aug2010, Vol. 33 Issue 4, p98
The author reflects on the ability of the pharmaceutical industry to contribute to the quality use of medicines in Australia. He mentions that the industry can make a beneficial contribution, but it depends on what they are rewarded for doing. Meanwhile, he states that there are hindrances...
- Meth Wars: A Letter to Goliath. Retsinas, Joan // Progressive Populist;10/1/2013, Vol. 19 Issue 17, p15
The article discusses the efforts of U.S. public officials to limit the easy access to pseudoephedrine, an ingredient both in methamphetamine and over-the-counter cough syrups, by requiring consumers and drug manufacturers to show a prescription before pharmacists will an order for cough syrup.
- Separating the wheat from the chaff. Runge, Claus // European Journal of Health Economics;Apr2012, Vol. 13 Issue 2, p121
The author reflects on the pharmaceutical market restructuring act (AMNOG), a new reimbursement and pricing system in Germany. The author says that the act requires the subjection of pharmaceutical products to a three-month benefit assessment process. An overview of the policymakers' intention...
- What's wrong with Pharmac? Ask Jackie Blue. // New Zealand Doctor;5/9/2007, p15
The article presents the views of National Party Member of Parliament (MP) Jackie Blues on the pharmaceutical policy implemented by the Pharmaceutical Management Agency of New Zealand (Pharmac). Blues says that Pharmac can not fund the research for anti-cancer drug Herceptin. She acknowledges...
- Positive PBS prospects. Tatchell, Michael // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p77
The article focuses on the sustainable cost of the Pharmaceutical Benefits Scheme (PBS) in Australia. The reforms of PBS are expected to offer substantial savings into the future, ensuring that PBS offers safe and effective medicines to the Australians. It points out that there is little or no...